Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program)

Trial Profile

Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms CAPRI-GOIM
  • Most Recent Events

    • 12 Sep 2017 Mature survival data (cut off date: April 30, 2017; n=98) presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results of liquid biopsy analysis (n=96) presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results assessing Eph A2 expression is a predictive biomarker of treatment efficacy, presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top